CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

We have used our established Glioblastoma cell models and gene expression analyses to characterize gene wild-type and CD70 knockdown GBM cell lines We utilized early passage Glioblastoma cell lines derived from primary patient samples of Glioblastoma in our work, as these samples are enriched for Brain Tumor Initiating Cells (BTICs) that are believed to initiate tumor formation. Briefly, we transduced each cell line with either shGFP or shCD70-knockdown lentiviral vectors, and confirmed knockdown of CD70 by flow cytometry. These lines were minimally cultured, collected, and sent for RNA sequencing analysis.

本研究依托已建立的胶质母细胞瘤（Glioblastoma，GBM）细胞模型与基因表达分析体系，对基因野生型及CD70敲低的GBM细胞系开展表征工作。本工作采用源自胶质母细胞瘤患者原代样本的早期传代细胞系，因此类样本富集了被认为可启动肿瘤形成的脑肿瘤起始细胞（Brain Tumor Initiating Cells, BTICs）。简言之，我们将各细胞系分别用shGFP慢病毒载体或shCD70敲低慢病毒载体进行转导，并通过流式细胞术验证了CD70的敲低效果。随后将这些经低限度培养、收集的细胞系送检，开展RNA测序分析。